Newsletter | March 12, 2020

03.12.20 -- What Could Transform Biologics Reimbursement?

 
Featured Editorial
Employers Aim To Transform Biosimilar, Biologics Reimbursement
 
By Anna Rose Welch, editor, Biosimilar Development

Though the IDN is a unique setting of care, there were still several lines of discussion that arose from Kaiser Permanente's best practices that sparked discussion on how other stakeholders, particularly employers, can start to chip away at the systemic issues standing in biosimilars’ way.

FDA’s Drug Shortages Root Cause Report: Does It Miss The Mark?
 
By Ben Locwin, Ph.D.

At the behest of Congress, an interagency Drug Shortage Task Force, led by the FDA, recently published the Drug Shortages: Root Causes and Potential Solutions report. Here, we unpack the four root causes for drug shortages as determined by the task force.

Industry Insights
Is Your Biologic At Risk For Protein Aggregation? Part 1
Article | By Martin Gonzalez, Ph.D., Pfizer CentreOne Contract Manufacturing

This is the first installment in a three-part series that examines what causes protein aggregation and practical steps you can take to mitigate the risk.

Scaling A mAb Production Process To A Single-Use Platform
White Paper | GE Healthcare Life Sciences

The transfer of mAb production processes between scales, referred to as scale-up or scale-down, is difficult. This study reviews moving mAb production from a microscale bioreactor to a single-use platform.

Connect With Biosimilar Development:
      Twitter